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We report a case of osteomyelitis caused by Enterobacter cancerogenus resistant to aminopenicillins in a
56-year-old male who had a motorcycle accident and suffered from multiple bone fractures with abundant
environmental exposure. E. cancerogenus has rarely been associated with human infections, and its clinical
significance remains unclear.
CASE REPORT
A previously healthy 56-year-old lawyer had a severe motor-
cycle accident, in which he was thrown onto the ground. He
suffered from an open fracture of the proximal third of the
right leg, a right acromioclavicular (AC) luxation and multiple
fractures in other body parts.
He immediately underwent surgery with reduction and ex-
ternal fixation of the open tibial fracture. A single dose of
cefamandole (2 g) given intravenously (i.v.) was administered
as prophylaxis at the time of anesthesia. Empirical therapy with
amoxicillin-clavulanic acid (2.2 g given i.v. every 8 h) and met-
ronidazole (500 mg given i.v. every 8 h) was introduced, start-
ing from the day following the intervention. A week later,
another surgery was performed in order to reduce the AC
luxation and to insert an external fixator on the right ulna.
Metronidazole therapy was stopped after 2 weeks.
Four weeks after admission, while on continued antibiotic
treatment with amoxicillin-clavulanic acid, the patient started
complaining of increasing leg pain, with concomitant appear-
ance of spontaneous purulent drainage from the wound on the
anterior tibial side. The patient remained apyretic with normal
white blood cells, an erythrocyte sedimentation rate of 38
mm/h, C-reactive protein level of 8.2 mg/liter (normal values, 0
to 5 mg/liter), and fibrinogen level of 445 mg/dl. An X-ray of
the right leg showed that the fracture had not healed.
A swab culture of the purulent wound grew Enterobacter
cancerogenus resistant to aminopenicillins (in the presence or
absence of -lactamase inhibitor) and to cefazoline: amoxicil-
lin-clavulanic acid was therefore stopped, and a new antibiotic
regimen consisting of levofloxacin (500 mg given i.v. once a
day) plus ceftriaxone (2 g given i.v. once a day) was chosen on
the basis of the susceptibility tests.
At the end of the fifth week, the patient underwent extensive
debridement with resection of infected and necrotic-appearing
areas of the tibial bone. An Ilizarov ring fixator was positioned.
E. cancerogenus was cultured again from the bone specimens
collected during the operation. The resistance pattern was un-
changed from that of the previous isolate, and no change in
antibiotic treatment was required. In the following days, the
rapid recovery of the lesion allowed the uneventful application
of a skin graft. An X-ray showed an overt tendency toward
healing, with newly formed bone tissue seen at the site of frac-
ture. Inflammatory markers returned to values in the normal
range.
The patient was discharged after 7 weeks of i.v. treatment
with levoxacin and ceftriaxone.
The National Nosocomial Infections Surveillance system in
the United States recently reported that nosocomial infections
caused by Enterobacter spp. are increasing and a matter of
concern (8). This trend has been confirmed all over Europe in
the last several years, with Enterobacter spp. accounting for 8%
of the microorganisms isolated from intensive care units (15).
At this time, there are 13 recognized species in the genus
Enterobacter. Enterobacter cloacae and Enterobacter aerogenes
are routinely isolated from human clinical specimens, while the
other species are mostly isolated from environmental or veg-
etal sources (5). Enterobacter cancerogenus is one of the five
new species identified over the last few years. Originally des-
ignated enteric group 19 and first ascribed to the genus Er-
winia, it has been transferred to the genus Enterobacter as a
senior synonym of Enterobacter taylorae when extensive taxo-
nomic investigations revealed its genetic identity to a microor-
ganism identified by Urose˘vic´ in 1966 and named Erwinia can-
cerogena (6). E. cancerogenus is a lactose-fermenting rod. E.
cancerogenus has a DNA relatedness of 61% to E. cloacae and
differs from it mostly by being ornithine decarboxylase negative
and D-arabinose positive.
E. cancerogenus exhibits natural resistance to aminopenicil-
lins (i.e., amoxicillin and amoxicillin-clavulanic acid) and/or to
narrow- and expanded-spectrum cephalosporins (i.e., cefaclor,
cefazoline, loracarbef, and cefoxitin). The -lactam phenotype
of E. cancerogenus is similar to that expressed by other well-
known Enterobacter spp. and indicates the presence of chro-
mosomally encoded AmpC -lactamases (Amber class C -lac-
tamases) (3, 12, 14).
In agreement with our finding, Pitout et al. found inducible
AmpC -lactamases in all E. cancerogenus strains examined
(n  6), with isoelectric point (pI) values of 9, suggesting an
enzyme similar to those found in the same study in wild-type
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strains of E. cloacae complex (pIs 8.0 to 9) and E. aerogenes
(pIs 8.4 to 8.8) (9).
The constitutive hyperproduction of AmpC is of major con-
cern, since it confers resistance to most -lactam antibiotics,
sparing only carbapenems and, amongst cephalosporins, only
cefepime. This phenotype commonly results from selective
antibiotic pressure, and Enterobacter isolates resistant to ex-
panded-spectrum cephalosporins are becoming a matter of
concern for the possibility of transmitting antibiotic resistance
from one microorganism to another worldwide. Outbreaks of
infections due to Klebsiella pneumoniae harboring plasmid-
encoded cephalosporinases and the spread of this resistance
mechanism to bacterial species naturally susceptible to cepha-
mycins have been reported (4).
So far, E. cancerogenus has been rarely found associated with
human infections, and only a few cases of acute or chronic
illnesses have been identified: E. cancerogenus infections seem
to occur mostly in the setting of contaminated wounds, even if
other exposures have been reported (Table 1).
The aim of our brief report is primarily to contribute to the
understanding of E. cancerogenus infections, to the knowledge
of the epidemiology, clinical manifestations, and therapeutic
options. In this case, the history of an open fracture following
a crush injury suggests an environmental, rather than nosoco-
mial, source of the organism: indeed, E. cancerogenus is gen-
erally recovered from environmental or vegetal sources and is
considered mostly phytopathogenic (1). Our strain displayed
an antibiotic susceptibility pattern similar to previously re-
ported patterns (10, 11, 13, 16) and was capable of causing the
same morbidity as other Enterobacter spp. or gram-negative
bacteria that cause acute osteomyelitis. Note that this patient
had an inappropriate 4-week antibiotic therapy administered
before E. cancerogenus grew in culture from a swab and the in
vitro susceptibility test was available. In conclusion, we suggest
that an E. cancerogenus infection should be considered in pa-
tients with traumatic injuries and secondary infection with a
microorganism identified as an Enterobacter species, especially
when treatment with aminopenicillin is unsuccessful or when
wound environmental contamination is plausible.
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